A research concept explores using ergothioneine, a rare amino acid with potent antioxidant properties, as a preventive approach for Alzheimer’s disease. The compound is proposed to cross the blood-brain barrier via the OCTN1 transporter, supporting neuroprotective effects. The approach includes incorporating ergothioneine extract into beverages and conducting a longitudinal human study to evaluate cognitive benefits and effects on oxidative stress.
A research concept explores ergothioneine, a rare amino acid with potent antioxidant properties, as a preventive measure against Alzheimer’s disease. Ergothioneine is proposed to cross the blood-brain barrier via the OCTN1 transporter, enabling targeted delivery to the brain. The concept aims to leverage ergothioneine’s neuroprotective potential to help reduce neurodegenerative risk over time.
Key features:
This research is currently at Technology Readiness Level 4, indicating that the concept has been validated in a laboratory setting. Future steps involve formulating the beverage and conducting a human study to assess its effectiveness in preventing oxidative stress and improving cognitive function.
Vanderbilt University Medical Center is a large, independent academic medical center and health system in Nashville, uniting patient care, research, and training at scale. Co-located hospitals and research facilities give partners access to core labs, biobanking, advanced imaging, and secure, de‑identified EHR data resources. A centralized trials office, experienced contracting, and proximity to Nashville’s healthcare management cluster streamline multi-site studies and real‑world evidence work. Research is backed by competitive federal funding, led by NIH and complemented by DoD and CDC. A dedicated technology transfer office supports IP, licensing, and startup formation to accelerate clinical translation.